Pfizer (PFE) Signs Sec61 Drug Discovery Deal With A Research Partner

• Pfizer (NYSE:PFE) signed a new research collaboration and license agreement with Enodia Therapeutics to develop Sec61-targeting small molecule drugs.
• The partnership gives Pfizer access to Enodia's proprietary Sec61 inhibitor discovery platform under a multi million dollar milestone and royalty structure.
• The deal extends Pfizer's early stage discovery efforts beyond its current late stage pipeline by focusing on potentially first in class therapeutics.
• This new Pfizer Enodia Sec61 drug discovery deal is worth weighing alongside the other factors covered in our Pfizer review. We have also spotted 4 warning signs worth knowing about at Pfizer.

For a broader view on how large drugmakers are tapping external research in areas like AI guided discovery, explore 33 healthcare AI stocks.

Pfizer is a large US pharmaceuticals group with a market cap of about $161.9 billion that develops and sells biopharmaceutical products globally. A deal like this fits into a broader push to source early science from outside partners rather than build every platform internally.

2 things going right for Pfizer that this headline doesn't cover.

How the Enodia partnership tests Pfizer’s launched-growth story

Pfizer’s Narrative hinges on launched and acquired products in oncology, obesity and other areas gradually replacing a shrinking COVID portfolio while heavy R&D and cost savings keep earnings intact. The Enodia Sec61 deal plugs straight into that bet by trying to seed another future oncology-like pillar from early science.

"Expansion of launched and acquired products, which management now describes as running at around a US$13b annualized revenue rate and growing in the 20% range..."

See how the full story points towards a $28.88 fair value for Pfizer.

The Enodia agreement leans into the bullish side of the Pfizer story that emphasizes oncology portfolio build out and broader use of AI-style discovery tools. It reinforces the idea that the group will not rely solely on the Seagen assets and late-stage agents, but will keep refreshing its early pipeline against competitors such as Merck and Bristol Myers Squibb.

The bear case is still visible in the fine print. This is another royalty-and-milestone structure that adds R&D commitments while analysts already flag high debt, uncovered dividends and reliance on cost programs for US$9.7b of savings through 2029. Whether this news tilts positive or negative depends on how much confidence you have that early-platform bets like Sec61 inhibitors will eventually join that launched US$13b product pool.

Updates like this only really matter if you have a clear view of the direction Pfizer is trying to move its earnings mix, which is exactly what an explicit Narrative forces you to spell out.

Add Pfizer to your Watchlist and get alerts as these catalysts play out.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com